StratDeck

Two stocks in Healthcare

Gilead Sciences vs McKesson: profit, growth, debt and price compared

McKesson is stronger on 3 of 6 figures: profit margin, sales growth and price trend. Gilead Sciences is stronger on 2: price for its expected profit and dividend.

Figures as of 18 November 2026SEC EDGARYahoo Finance
Explore Gilead Sciences' storyWhere next ↓

Save both stocks to your watchlist and revisit their latest fundamentals.

Gilead Sciences and McKesson side by side
Gilead SciencesGILDMcKessonMCK
Net margin−12.5%Stronger: 1.1%
Revenue growth, past year+6.83%Stronger: +7.57%
Debt to equity202.5%—
Forward P/EStronger: 16.6×20.7×
Dividend yieldStronger: 1.92%0.31%
AnalystsBuy · 26Buy · 14
From its 200-day average+19.3%Stronger: +22.8%

Share price over the past year

  • Gilead Sciences+32.9%
  • McKesson+26.0%

18 Nov 202518 Nov 2026

Gilead Sciences or McKesson: which is stronger?

  • MCK

    Which is more profitable?

    McKesson keeps more of each sale as profit: 1.1% against −12.5%.

  • MCK

    Which is growing its sales faster?

    McKesson is growing its sales faster: +7.57% over the past year, against +6.83%.

  • GILD

    Which costs less for the profit it is expected to make?

    Gilead Sciences costs less for the profit it is expected to make: 16.6× its forward earnings, against 20.7×.

  • GILD

    Which pays more in dividends?

    Gilead Sciences pays more back in dividends for what a share costs: 1.92% a year, against 0.31%.

  • Which do analysts rate higher?

    Analysts rate both the same: Buy.

  • MCK

    Which is in the stronger price trend?

    McKesson's price is in the stronger trend: 22.8% above its 200-day average, against 19.3% above.

What each company does

GILDGilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

Reports results on 9 February 2027

MCKMcKesson

McKesson Corporation provides healthcare services in the United States and internationally.

Reports results on 3 February 2027

This comparison is just the starting point.

Discover opportunities, understand companies and compare investments in one place. See how StratDeck works

Keep researching

Where next

Every US healthcare comparison

Free email

Up to speed in minutes, four times a week

Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.

Early access

Become a StratDeck founding user

Use StratDeck, tell us what's missing, and help decide what we build next.

100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.